Knight Therapeutics Inc.

GUD.TOTSXHealthcare● Active

$9.14

+$0.53(+6.16%)

Market Cap$896037158

P/E Ratio—

52W High$9.25

52W Low$5.66

Avg Volume87K

Open$8.50

Beta0.07

Free Cash Flow Financials Revenue

Knight Therapeutics Inc. (GUD.TO) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

GUD.TO · free cash flow · updated Jun 8, 2026

Core FCF metrics

GUD.TO · FCF · TTM · margin & CAGR

Free cash flow was $68.4M for FY2025 (fiscal year ending 2025-12-31), up 1322.5% year-over-year The FCF margin was 15.2%.

FY2025 Free Cash Flow$68.4M▲ +1322.5% YoY

Trailing 12M (TTM)$76.2Mtrailing 4 quarters sum

FCF Margin15.2%$68.4M ÷ revenue

3-Year CAGR+67.1%FY2022 → FY2025

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

GUD.TO · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$70.3M(2M)$68.4M▲ +1322.5%15.2%

FY2024$36.3M(31M)$4.8M▼ 81.5%1.3%

FY2023$35.9M(10M)$26.0M▲ +77.2%7.9%

FY2022$40.5M(26M)$14.7M▲ +108.2%5.0%

FY2021$44.6M(224M)−$179.6M▼ 446.2%-73.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

GUD.TO · P/FCF · FCF yield · FCF per share

Knight Therapeutics Inc. (GUD.TO) trades at a FCF yield of 8.58% and a price-to-free-cash-flow ratio of 11.9x. FCF per share stands at $0.77, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

8.58%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.77

TTM FCF ÷ Shares Outstanding

Price / FCF

x11.9

Share Price ÷ FCF per Share

EV / FCF (TTM)

x11.2

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

GUD.TO · cash flow statement · operating / investing / financing

For FY2025, Knight Therapeutics Inc. generated $70.3M in operating cash flow and spent 2M in capital expenditures, yielding $68.4M in free cash flow.

Operating Activities

+$70.3M

Cash from core business operations

2025-12-31

Investing Activities

−$84.1M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$13.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($70.3M) − |CapEx| (2M) = FCF ($68.4M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

GUD.TO vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Knight Therapeutics Inc.YOU

GUD.TO

$68.4M+1322.5%15.2%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Knight Therapeutics Inc. (GUD.TO) reported free cash flow of $68.4M for FY2025 (fiscal year ending 2025-12-31), up 1322.5% year-over-year. The FCF margin was 15.2%.

Based on available data, Knight Therapeutics Inc. has maintained positive free cash flow for at least 9 fiscal year(s). FCF peaked at $68.4M in FY2025.

Knight Therapeutics Inc.'s FCF yield is 8.58% and price-to-FCF ratio is 11.9x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

GUD.TO free cash flow · 8 questions

Knight Therapeutics Inc. free cash flow was $68.4M for FY2025, up 1322.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $76.2M.

GUD.TO free cash flowGUD.TO FCFGUD.TO FCF 2025GUD.TO free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Knight Therapeutics Inc. · Knight Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026